Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo(Kindai University), Hajime Aino, Nobukazu Tanabe(Sendai Medical Center), Takuji Torimura(Omuta hospital), Takahiro Yamasaki(Yamaguchi University), Shunsuke Nojiri(Nagoya City University), Masafumi Ikeda(National Cancer Center Hospital East), Keisuke Hino(Yamaguchi University), Norihiro Kokudo(National Center for Global Health and Medicine), Teiji Kuzuya(Nagoya University), Kazuhiko Nakao(Nagasaki University), Hiroshi Aikata(Hiroshima Prefectural Hospital), Philip J. Johnson(Prince of Wales Hospital), Naoto Kawabe(Fujita Health University), Kenichi Yoshimura(Hiroshima University), Junji Furuse(Kanagawa Prefectural Hospital Organization), Hidetaka Tsumura(Hyogo Prefectural Cancer Center), Namiki Izumi(Musashino Red Cross Hospital), Yasuaki Arai(Tokyo National Hospital), Takuji Okusaka(National Cancer Centre Japan), Kazuomi Ueshima(Kindai University), Yoshiyuki Wada(National Kyushu Medical Center), Sadahisa Ogasawara(Chiba University), Norio Isoda(Jichi Medical University), Kiwamu Okita(Tokuyama (Japan)), Michihisa Moriguchi(Kyoto Prefectural University of Medicine), Akio Ido(Kagoshima University)
Cited by 134
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k